apatinib + temozolomide

Apatinib + temozolomide is an investigational oral combination regimen used primarily in the treatment of recurrent glioblastoma (rGBM). Apatinib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting tumor angiogenesis. Temozolomide is an oral alkylating agent that induces DNA damage, leading to tumor cell apoptosis. The combination has demonstrated promising efficacy and manageable toxicity in clinical studies for rGBM, with evidence suggesting it may be more effective than temozolomide monotherapy, particularly in patients with unmethylated MGMT and wild-type IDH. Both drugs are orally administered, potentially improving patient adherence and convenience[1][2][3][4].

Brand names

AitanTemodarTemodal

Other names

RivoceranibApatinib mesylate